|
LM_ID
|
Common Name
|
Systematic Name
|
Main class
|
Sub class
|
Mass
|
Formula
|
|
LMFA04000091
|
Resolvin T1
|
7,13,20-Trihydroxy-8E,10Z,14E,16Z,18E-docosapentaenoic acid
|
Docosanoids [FA04]
|
Other Docosanoids [FA0400]
|
378.24
|
C22H34O5
|
|
LMFA04000092
|
Resolvin T2
|
7,8,13-Trihydroxy-9E,11E,14E,16Z,19Z-docosapentaenoic acid
|
Docosanoids [FA04]
|
Other Docosanoids [FA0400]
|
378.24
|
C22H34O5
|
|
LMFA04000093
|
Resolvin T3
|
7,12,13-Trihydroxy-8Z,10E,14E,16Z,19Z-docosapentaenoic acid
|
Docosanoids [FA04]
|
Other Docosanoids [FA0400]
|
378.24
|
C22H34O5
|
|
LMFA04010049
|
10,13-diepi-10-F4c-NeuroP
|
(R,4Z,7Z,11E)-12-((1S,2S,3R,5S)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010048
|
10,13-diepi-10-F4t-NeuroP
|
(R,4Z,7Z,11E)-12-((1R,2R,3R,5S)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010117
|
10,17-diepi-17-F4c-NeuroP
|
(4Z,7Z)-9-((1S,2S,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010116
|
10,17-diepi-17-F4t-NeuroP
|
(4Z,7Z)-9-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010047
|
10-epi-10-F4c-NeuroP
|
(R,4Z,7Z,11E)-12-((1R,2S,3R,5S)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010050
|
10-epi-10-F4t-NeuroP
|
(R,4Z,7Z,11E)-12-((1S,2R,3R,5S)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010121
|
10-epi-17-F4c-NeuroP
|
(4Z,7Z)-9-((1S,2S,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010120
|
10-epi-17-F4t-NeuroP
|
(4Z,7Z)-9-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010041
|
10-epi-7-F4c-NeuroP
|
(S,4Z,8E)-9-((1S,2S,3R,5S)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010040
|
10-epi-7-F4t-NeuroP
|
(S,4Z,8E)-9-((1R,2R,3R,5S)-3,5-dihydroxy-2-((2Z,5Z)-octa-2,5-dien-1-yl)cyclopentyl)-7-hydroxynona-4,8-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010055
|
10-F4c-NeuroP
|
(S,4Z,7Z,11E)-12-((1R,2S,3R,5S)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010005
|
10-F4-NeuroP
|
(4Z,7Z,11E)-12-(3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010058
|
10-F4t-NeuroP
|
(S,4Z,7Z,11E)-12-((1S,2R,3R,5S)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010063
|
11-epi-11-F4c-NeuroP
|
3-((1R,2S,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010066
|
11-epi-11-F4t-NeuroP
|
3-((1S,2R,3S,5R)-3,5-dihydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010071
|
11-F4c-NeuroP
|
3-((1R,2S,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010006
|
11-F4-NeuroP
|
3-(3,5-dihydroxy-2-((1E,5Z,8Z,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010074
|
11-F4t-NeuroP
|
3-((1S,2R,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z,8E,11Z)-3-hydroxytetradeca-1,5,8,11-tetraen-1-yl)cyclopentyl)propanoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010081
|
13,16-diepi-13-F4c-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,2S,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010080
|
13,16-diepi-13-F4t-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,2R,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010133
|
13,20-diepi-20-F4c-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2S,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010132
|
13,20-diepi-20-F4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010057
|
13-epi-10-F4c-NeuroP
|
(S,4Z,7Z,11E)-12-((1S,2S,3R,5S)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010056
|
13-epi-10-F4t-NeuroP
|
(S,4Z,7Z,11E)-12-((1R,2R,3R,5S)-3,5-dihydroxy-2-((Z)-pent-2-en-1-yl)cyclopentyl)-10-hydroxydodeca-4,7,11-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010079
|
13-epi-13-F4c-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1R,2S,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010082
|
13-epi-13-F4t-NeuroP
|
(R,4Z,7Z,10Z,14E)-15-((1S,2R,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010137
|
13-epi-20-F4c-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2S,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010136
|
13-epi-20-F4t-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010087
|
13-F4c-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,2S,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010003
|
13-F4-NeuroP
|
(4Z,7Z,10Z,14E)-15-(2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010090
|
13-F4t-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,2R,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010099
|
14-epi-14-F4c-NeuroP
|
(Z)-6-((1R,2S,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010102
|
14-epi-14-F4t-NeuroP
|
(Z)-6-((1S,2R,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010103
|
14-F4c-NeuroP
|
(Z)-6-((1R,2S,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010004
|
14-F4-NeuroP
|
(Z)-6-(3,5-dihydroxy-2-((1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010106
|
14-F4t-NeuroP
|
(Z)-6-((1S,2R,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010089
|
16-epi-13-F4c-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1S,2S,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010088
|
16-epi-13-F4t-NeuroP
|
(S,4Z,7Z,10Z,14E)-15-((1R,2R,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010115
|
17-epi-17-F4c-NeuroP
|
(4Z,7Z)-9-((1R,2S,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010118
|
17-epi-17-F4t-NeuroP
|
(4Z,7Z)-9-((1S,2R,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010119
|
17-F4c-NeuroP
|
(4Z,7Z)-9-((1R,2S,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010002
|
17-F4-NeuroP
|
(4Z,7Z)-9-(3,5-dihydroxy-2-((1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010122
|
17-F4t-NeuroP
|
(4Z,7Z)-9-((1S,2R,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010131
|
20-epi-20-F4c-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010134
|
20-epi-20-F4t-NeuroP
|
(4Z,7Z,10Z)-12-((1S,2R,3R,5S)-3,5-dihydroxy-2-((R,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010135
|
20-F4c-NeuroP
|
(4Z,7Z,10Z)-12-((1R,2S,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|
|
LMFA04010001
|
20-F4-NeuroP
|
(4Z,7Z,10Z)-12-(3,5-dihydroxy-2-((E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid
|
Docosanoids [FA04]
|
Neuroprostanes [FA0401]
|
378.24
|
C22H34O5
|